Premium
Moclobemide versus clomipramine in the treatment of depression: a single‐centre study, Federal Republic of Germany
Author(s) -
Funke H. J.,
Moritz E.,
Hellstern K.,
Malanowski H.
Publication year - 1990
Publication title -
acta psychiatrica scandinavica
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 2.849
H-Index - 146
eISSN - 1600-0447
pISSN - 0001-690X
DOI - 10.1111/j.1600-0447.1990.tb05326.x
Subject(s) - moclobemide , clomipramine , depression (economics) , endogenous depression , psychology , medicine , rating scale , psychiatry , endogeny , antidepressant , anxiety , economics , macroeconomics , developmental psychology
Moclobemide was compared with clomipramine for safety and efficacy in 2 groups of 15 patients each with endogenous depression. The drugs were given under double‐blind conditions in increasing doses; 1 patient in the moclobemide group dropped out because of lack of efficacy. Mean final improvement on the Hamilton Rating Scale for Depression was 51% in the moclobemide group and 54% in the clomipramine group. Efficacy and tolerance were rated good or very good by 47% (moclobemide) and 53%o (clomipramine) (NS). The results indicate that moclobemide is as effective as clomipramine in treating endogenous depression.